David Sherris

904 total citations
27 papers, 740 citations indexed

About

David Sherris is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, David Sherris has authored 27 papers receiving a total of 740 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 6 papers in Immunology and 6 papers in Cancer Research. Recurrent topics in David Sherris's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Immune Cell Function and Interaction (4 papers). David Sherris is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Immune Cell Function and Interaction (4 papers). David Sherris collaborates with scholars based in United States, Netherlands and Italy. David Sherris's co-authors include Jeffrey G. Jacot, John S. Parkinson, Laura E. Benjamin, Benjamin D. Hopkins, Carole Perruzzi, Durga Udayakumar, Qi Xue, George A. Heavner, Alexander H. Taylor and Mark Nedelman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

David Sherris

25 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Sherris United States 16 459 119 102 92 88 27 740
Jongkyu Choi United States 19 1.0k 2.2× 164 1.4× 70 0.7× 49 0.5× 120 1.4× 31 1.2k
Ding Wu China 14 424 0.9× 89 0.7× 87 0.9× 27 0.3× 139 1.6× 27 734
Yunzhao R. Ren United States 10 528 1.2× 153 1.3× 81 0.8× 32 0.3× 340 3.9× 16 942
Lin Zheng China 12 341 0.7× 376 3.2× 202 2.0× 95 1.0× 152 1.7× 27 812
Zepeng Du China 18 622 1.4× 123 1.0× 202 2.0× 35 0.4× 257 2.9× 53 1.1k
Z. Mishal France 19 487 1.1× 157 1.3× 238 2.3× 17 0.2× 102 1.2× 32 922
Ning Zhu China 18 393 0.9× 105 0.9× 140 1.4× 18 0.2× 194 2.2× 41 691
George D.J. Green United States 11 244 0.5× 121 1.0× 64 0.6× 99 1.1× 195 2.2× 11 623
Yahya Tamimi Oman 15 465 1.0× 206 1.7× 29 0.3× 21 0.2× 181 2.1× 36 821
Simon Brunner Austria 14 896 2.0× 133 1.1× 43 0.4× 223 2.4× 389 4.4× 41 1.4k

Countries citing papers authored by David Sherris

Since Specialization
Citations

This map shows the geographic impact of David Sherris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sherris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sherris more than expected).

Fields of papers citing papers by David Sherris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sherris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sherris. The network helps show where David Sherris may publish in the future.

Co-authorship network of co-authors of David Sherris

This figure shows the co-authorship network connecting the top 25 collaborators of David Sherris. A scholar is included among the top collaborators of David Sherris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sherris. David Sherris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Torr, Elizabeth, et al.. (2017). The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation. Journal of Cellular Biochemistry. 118(8). 2241–2249. 17 indexed citations
3.
Gravina, Giovanni Luca, Francesco Marampon, David Sherris, et al.. (2014). Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1‐mediated survivin function and delaying DNA repair in prostate cancer models. The Prostate. 74(8). 852–868. 31 indexed citations
4.
Gerald, Damien, Irit Adini, Sharon Shechter, et al.. (2013). RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nature Communications. 4(1). 2824–2824. 51 indexed citations
5.
Lin, Fan, Levi C.M. Buil, David Sherris, Jos H. Beijnen, & Olaf van Tellingen. (2013). Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2. International Journal of Cancer. 133(5). 1222–1233. 28 indexed citations
6.
Syed, Farhatullah, David Sherris, Ralf Paus, et al.. (2012). Keloid Disease Can Be Inhibited by Antagonizing Excessive mTOR Signaling With a Novel Dual TORC1/2 Inhibitor. American Journal Of Pathology. 181(5). 1642–1658. 41 indexed citations
7.
Gravina, Giovanni Luca, Francesco Marampon, Leda Biordi, et al.. (2011). The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocrine Related Cancer. 18(4). 385–400. 28 indexed citations
8.
Lin, Fan, David Sherris, Jos H. Beijnen, & Olaf van Tellingen. (2011). High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. Journal of Chromatography B. 879(32). 3823–3831. 3 indexed citations
9.
Tao, Xiang, Yulin Jia, David Sherris, et al.. (2011). Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene. 30(21). 2443–2450. 45 indexed citations
10.
11.
Nguewa, Paul, Juan A. Díaz-González, Ernest Hamel, et al.. (2009). The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. British Journal of Cancer. 100(6). 932–940. 42 indexed citations
12.
Lin, Fan, Levi C.M. Buil, Jos H. Beijnen, David Sherris, & Olaf van Tellingen. (2009). Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood-brain barrier and may be an attractive agent for treatment of glioblastoma. Molecular Cancer Therapeutics. 8(12_Supplement). A148–A148. 1 indexed citations
13.
Xue, Qi, Benjamin D. Hopkins, Carole Perruzzi, et al.. (2008). Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability. Cancer Research. 68(22). 9551–9557. 87 indexed citations
14.
Sherris, David. (2007). Ocular drug development - Future Directions. Angiogenesis. 10(2). 71–76. 29 indexed citations
15.
Watanabe, Hiroshi, David Sherris, & Gary S. Gilkeson. (1998). Soluble CD16 in the Treatment of Murine Lupus Nephritis. Clinical Immunology and Immunopathology. 88(1). 91–95. 9 indexed citations
16.
Taylor, Alexander H., George A. Heavner, Mark Nedelman, et al.. (1995). Lipopolysaccharide (LPS) Neutralizing Peptides Reveal a Lipid A Binding Site of LPS Binding Protein. Journal of Biological Chemistry. 270(30). 17934–17938. 66 indexed citations
17.
Sherris, David, et al.. (1994). Techniques in Periocular Reconstruction. Facial Plastic Surgery. 10(2). 202–213. 1 indexed citations
18.
Mayer, L, et al.. (1991). Cytokines regulating human B cell growth and differentiation. Clinical Immunology and Immunopathology. 61(2). S28–S36.
19.
Shaked, A., David Sherris, & L Mayer. (1988). Isolation of fibroblast proliferation factor: distinction from interleukin-1.. PubMed. 44(6). 487–90. 1 indexed citations
20.
Spangrude, Gerald J., David Sherris, & Raymond A. Daynes. (1982). INHIBITORY EFFECTS OF VARIOUS OXYGENATED STEROLS ON THE DIFFERENTIATION AND FUNCTION OF TUMOR-SPECIFIC CYTOTOXIC T LYMPHOCYTES. Transplantation. 33(5). 482–491. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jongkyu Choi Breakdown of academic impact, for papers by Ding Wu Breakdown of academic impact, for papers by Yunzhao R. Ren Breakdown of academic impact, for papers by Lin Zheng Breakdown of academic impact, for papers by Zepeng Du Breakdown of academic impact, for papers by Z. Mishal Breakdown of academic impact, for papers by Ning Zhu Breakdown of academic impact, for papers by George D.J. Green Breakdown of academic impact, for papers by Yahya Tamimi Breakdown of academic impact, for papers by Simon Brunner
Rankless by CCL
2026